ClinicalTrials.gg
CompletedNCT03076853MATRIX-DPRSUpdated Mar 10, 2017

Medication Assessment Through Real Time Information eXchange - Distributed Pharmaceutical Record System

An observational study in Patients With Pharmaceutical Record, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by Centre Hospitalier Universitaire de Nice · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
511
Ages
18 Years and older
Sex
All
01

Study summary

The aim of MATRIX-DPRS is to assess the clinical and organizational impacts of the use of the medication record, opened, filled and managed by pharmacists (from private office and hospital units) by hospital physicians in private and public healthcare establishments (volunteers), for three clinical contexts: anaesthesiology visit before surgery, medications abuse and emergency hospitalization, medications and elderly hospitalisations.

Read the detailed description

As part of the national 2012 PREPS call for proposals, a multidisciplinary research team was set up to design and develop methods in order to evaluate the efficiency and the performance of health data information systems. This team is composed of physicians and researchers in medical informatics, hospital information systems, biostatistics, process analysis and management in healthcare, ergonomics and usability. This study was aimed to evaluate the clinical and organizational impacts of the use of a new source of information brought by the pharmaceutical record, promoted by the national committee of pharmacists. This record is opened and filled for each patient by the pharmacist. It contains all the medication sold (prescribed by physician and OTC) by the patient. This record is used by almost all the private pharmacists. The French Health Ministry was looking for an evaluation of this new source of information by hospital physicians in order to be applied by any healthcare institution or organization wishing to evaluate the added value of its investments or recommendations (example: ARS (French Regional Health Agency), DGOS (French Directorate General of Health Services), etc.) in the information system.

02

Conditions studied

  • Patients With Pharmaceutical Record
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 722 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in Anesthesia, Emergency and Geriatric departments with Pharmaceutical Record

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concerning Anesthesia department:

  • Patients in pre-anesthesia consultation for scheduled intervention.

Concerning Emergencies department:

  • Patients admitted for fainting fit

Regarding patients hospitalized in geriatrics:

  • Patients admitted to geriatrics

Exclusion criteria

Exclusion Criteria:

  • Minors
  • Patients without administrative or judicial freedom if the authorization of the legal representative can not be collected.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
511 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with Pharmaceutical Record

    Other: Opening of the Pharmaceutical Record

Interventions

  • OtherOpening of the Pharmaceutical Record

    After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.

06

What researchers measure

Primary outcomes

  1. Modification of the medical prescription linked to the use of the pharmaceutical record

    The primary outcome measure is to evaluate the impact of the use of the pharmaceutical record on th medical prescription. The doctor writes a first medical prescription without using the pharmaceutical record and a second with the pharmaceutical record.The changes are analyzed.

    Time frame: 3 months

07

Study locations

1 site
  • CHU de Nice
    Nice, 06000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Jun 2016, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2017
First posted
Mar 10, 2017
StartActual
Apr 3, 2016
Primary completionActual
Jun 30, 2016
CompletionActual
Jun 30, 2016
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03076853
Responsible party
Sponsor
First posted
Mar 10, 2017
Start date
Apr 3, 2016
Primary completion
Jun 30, 2016
Completion
Jun 30, 2016
Last update
Mar 10, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion